{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:40:01Z","timestamp":1790664001105,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.esmoop.2022.100601","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T23:24:28Z","timestamp":1667863468000},"page":"100601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)"],"prefix":"10.1016","volume":"7","author":[{"given":"M.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"L\u00fcbbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Thill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Furlanetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reinisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mundhenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-O.","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Denkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"van Mackelenbergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Fasching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Burchardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Nekljudova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100601_bib1","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100601_bib2","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100601_bib3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000516420","article-title":"AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2021","volume":"16","author":"Thill","year":"2021","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.esmoop.2022.100601_bib4","doi-asserted-by":"crossref","first-page":"R337","DOI":"10.1530\/ERC-16-0121","article-title":"Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies","volume":"23","author":"Murphy","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.esmoop.2022.100601_bib5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/ijms22010173","article-title":"PI3K\/AKT\/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects","volume":"22","author":"Miricescu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.esmoop.2022.100601_bib6","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv Ther"},{"key":"10.1016\/j.esmoop.2022.100601_bib7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100601_bib8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10549-021-06173-z","article-title":"Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES","volume":"188","author":"Im","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2022.100601_bib9","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS18-P6-18-08","article-title":"Abstract P6-18-08: Everolimus\u00a0+ exemestane for HR+ advanced breast cancer in routine clinical practice \u2013 final results from the non-interventional trial, BRAWO. In Poster Session Abstracts: American Association for Cancer Research","volume":"79","author":"L\u00fcftner","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2022.100601_bib10","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/ijc.31738","article-title":"Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: results of the single-arm, phase IIIB 4EVER trial","volume":"144","author":"Tesch","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2022.100601_bib11","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s12094-020-02327-5","article-title":"Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population","volume":"22","author":"Ciruelos","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.esmoop.2022.100601_bib12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.breast.2020.01.035","article-title":"Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2\u2013 advanced breast cancer progressing on\/after prior endocrine therapy in routine clinical practice: primary results from the non-interventional study","volume":"50","author":"Steger","year":"2020","journal-title":"STEPAUT. Breast"},{"key":"10.1016\/j.esmoop.2022.100601_bib13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/annonc\/mdv595","article-title":"Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy","volume":"27","author":"Rugo","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100601_bib14","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1002\/cncr.28010","article-title":"Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial","volume":"119","author":"Burris","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2022.100601_bib15","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","article-title":"Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial","volume":"18","author":"Rugo","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100601_bib16","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP Guideline Update","volume":"38","author":"Allison","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100601_bib17","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100601_bib18","unstructured":"WHO handbook for reporting results of cancer treatment. 48. WHO offset publication, Geneva: WHO;\u00a01979."},{"key":"10.1016\/j.esmoop.2022.100601_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2022.100601_bib21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.esmoop.2022.100601_bib22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.esmoop.2022.100601_bib23","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/17425255.2019.1663169","article-title":"Molecular basis for class side effects associated with PI3K\/AKT\/mTOR pathway inhibitors","volume":"15","author":"Zhang","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.esmoop.2022.100601_bib24","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/annonc\/mdu009","article-title":"Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2","volume":"25","author":"Rugo","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100601_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/onco.13609","article-title":"Everolimus plus exemestane treatment in patients with metastatic hormone receptor-positive breast cancer previously treated with CDK4\/6 inhibitor therapy","volume":"26","author":"Cook","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2022.100601_bib26","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1634\/theoncologist.2018-0340","article-title":"Evaluation of miracle mouthwash plus hydrocortisone versus prednisolone mouth rinses as prophylaxis for everolimus-associated stomatitis: a randomized phase II study","volume":"24","author":"Jones","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2022.100601_bib27","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.annonc.2021.02.003","article-title":"Efficacy of everolimus in patients with HR+\/HER2\u2013 high risk early stage breast cancer","volume":"32","author":"Bachelot","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100601_bib28","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2017.35.15_suppl.1061","article-title":"Analysis of everolimus starting dose as prognostic marker in HR+ mBC patients treated with everolimus (EVE)\u00a0+ exemestane (EXE): Results of the 3rd interim analysis of the non-interventional trial BRAWO","volume":"35","author":"Fasching","year":"2017","journal-title":"J\u00a0Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922002319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922002319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T09:25:03Z","timestamp":1718789103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922002319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2059702922002319"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100601","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100601"}}